In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2011’s Top Biopharma Dealmakers

Executive Summary

Big Pharma entered into fewer in-licensing deals in 2011 than it did in 2010. Top M&As focused on emerging markets. And neurology, cancer and metabolic disease were the most lucrative therapeutic areas in alliances.

You may also be interested in...



Biopharma In 2011: A Year Of Transition

If 2010 was the year when pharma introduced new models, 2011 was the year it discovered that executing on its plans required a new mindset. There was a realization that pharma input and capital were required at the earliest stages of company creation. Innovation remained the order of the day, though pharma’s attempts to innovate looked strikingly similar to one another. We continued to see risk-sharing deal structures, emphasis on emerging markets, ongoing externalization and the biotech-ification of pharma, and stronger emphasis on “unmet medical need. Pharma also did more to work with VCs, payors, generics companies, and each other. The year saw a recovery in US drug approvals and launches, but the high prices associated with some of those new therapies and austerity in Europe also shed light on the health technology assessment-dominated future that likely faces most markets, including the US.

GermBloc Hand-Sanitizer Class Action Takes Aim At 99.99% Germ-Killing Claim

Like other hand sanitizer manufacturers, WillSpeed Technology claims its GermBloc “kills 99.99% of germs.” Plaintiffs in a proposed class action filed in Massachusetts federal court allege the claim “grossly overstates” the product’s efficacy, deceiving consumers and endangering them with false confidence.

Keeping Track: US FDA Set For Speed With Approvals Of Inqovy, Rukobia, Dojolvy, Phesgo; Keytruda Loses Chance At AA In HCC

The latest drug development news and highlights from the Pink Sheet’s FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

LL1128165

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel